ArticleAmerican journal of translational research2021
Early diagonosis of ovarian cancer: serum HE4, CA125 and ROMA model.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Morphological and molecular characterization of epithelial ovarian cancer: SEOM-SEAP consensus guidelines for biomarker integration in clinical practice.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Guideline
- Plasma level of human epididymis protein 4 is associated with risk of future venous thromboembolism-the Trøndelag Health study.Journal of thrombosis and haemostasis : JTH · 2026Article
- Minimal Residual Disease Detection: Bridging Molecular and Clinical Strategies for Recurrence Prevention in Gynecologic Cancers.International journal of molecular sciences · 2025Review
- A Novel Serum-Based Bioassay for Quantification of Cancer-Associated Transformation Activity: A Case-Control and Animal Study.Diagnostics (Basel, Switzerland) · 2025Article
- Multi-analyte approach combining cfDNA sequencing and protein testing for early ovarian cancer detection.iScience · 2025Article
- Diagnostic role of urine human epididymis protein 4 in ovarian cancer.Biochemia medica · 2024Review
- The diagnostic performance of the Mindray system in detecting CA125 and HE4 for patients with ovarian cancer.Translational cancer research · 2024Article
- Prediction of ovarian cancer using artificial intelligence tools.Health science reports · 2024Article
- Diagnostic Utility of Selected Matrix Metalloproteinases (MMP-2, MMP-3, MMP-11, MMP-26), HE4, CA125 and ROMA Algorithm in Diagnosis of Ovarian Cancer.International journal of molecular sciences · 2024Article
- Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer.Scientific reports · 2024Article
- Detection of serum HE4 levels contributes to the diagnosis of lung cancer.Oncology letters · 2023Article
- Clinical Value of Combined Multi-Indicator Tests in Diagnosis of Benign Ovarian.International journal of general medicine · 2023Article
- Molecular Biomarkers for the Early Detection of Ovarian Cancer.International journal of molecular sciences · 2022Review
- Clinical effects of TP-based hyperthermic intraperitoneal chemotherapy (HIPEC) on CD133 and HE4 expression in advanced epithelial ovarian cancer.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the diagnostic value of serum human epididymal protein 4 (HE4), carbohydrate antigen 125 (CA125), and risk of ovarian malignancy algorithm (ROMA) in early identification in ovarian cancer.
methodA total of 50 patients with ovarian cancer and 50 patients with benign ovarian tumors admitted to our hospital from January 2019 to January 2020 were included in Group A and Group B, respectively, and 50 healthy adult females during the same period were assigned to the blank group. The serum levels of HE4 and CA125 in each group were determined, and the ROMA of them was calculated according to postmenopausal status. The sensitivity, specificity, and positive diagnosis rate of HE4, CA125, and ROMA were calculated, and ROC curves were drawn to compare the diagnostic value of the three.
resultsGroup A showed significantly higher serum levels of HE4 and CA125 and a significantly higher ROMA than Group B and the blank group (both P<0.05). No significant difference was found in the serum level of HE4 between Group B and the blank group (P>0.05). The serum level of CA125 and ROMA were significantly higher in Group B when compared with those of the blank group (both P<0.05). The diagnostic sensitivity and positive diagnosis rate of the three indexes, from high to low, were HE4+CA125+ROMA>ROMA>HE4>CA125 (all P<0.05). The diagnostic specificity and the area under the curve (AUC) of the three indexes, from high to low, were HE4+CA125+ROMA>HE4>ROMA>CA125 (all P<0.05). Histologic grading and lymph node metastasis were factors affecting the serum levels of HE4, CA125, and ROMA in patients with ovarian cancer.
conclusionThe combined detection of HE4, CA125, and ROMA is more effective than diagnosis with any single indicator, so the combined diagnosis has a high application value in the early diagnosis of ovarian cancer.
Indexed as
Identifiers
35035759PMC8748147W4206861166What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.